EU's CHMP recommends fifth H1N1 vaccine and intravenous Relenza
This article was originally published in Scrip
The EU's CHMP has backed the conditional approval of Sanofi-Pasteur's adjuvanted H1N1 influenza vaccine Humenza for the prophylaxis of influenza in an officially declared pandemic situation.
You may also be interested in...
Somaxon Pharmaceuticals and Procter & Gamble Pharmaceuticals are to co-promote Somaxon's insomnia drug Silenor (low-dose doxepin) in the US.
GlaxoSmithKline has begun the Phase III clinical trials programme for its adjuvanted vaccine candidate (GSK1437173A) against herpes zoster for the prevention of shingles.
The EMA has accepted Optimer Pharmaceuticals' MAA for its narrow-spectrum antibiotic fidaxomicin for the treatment of Clostridium difficile infection (CDI) and for the prevention of recurrences of CDI.